Key Insights Pro Medicus' significant insider ownership suggests inherent interests in company's expansion 52% of ...

Pro Medicus (ASX:PME) has had a great run on the share market with its stock up by a significant 28% over the last three months. Since the market usually pay for a company’s long-term fundamentals, we ...

The average one-year price target for Pro Medicus (ASX:PME) has been revised to 76.25 / share. This is an increase of 6.31% from the prior estimate of 71.72 dated August 31, 2023. The price target is ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from Pro ...

Pro Medicus Limited ( ($AU:PME) ) just unveiled an announcement. Pro Medicus Limited has disclosed a small on-market share purchase by ...

Pro Medicus Ltd. Annual stock financials by MarketWatch. View the latest PME financial statements, income statements and financial ratios.

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Pro Medicus (ASX:PME) from Buy to Hold. As of April 2, 2025, the average one-year price target for Pro Medicus ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

Pro Medicus Ltd. engages in the development and supply of healthcare imaging software, Radiology Information System (RIS), and services to hospitals. It operates through the following geographical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.